Cardioversion of atrial fibrillation

Progress in Cardiovascular Diseases

Volumn 48, Issue 2, 2005, Pages 88-107

  Gowda, Subhashini A ^a   Shah, Arti ^a   Steinberg, Jonathan S ^a,b  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMBASILIDE; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; AZIMILIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DOFETILIDE; DRONADERONE; FLECAINIDE; IBUTILIDE; PILSICAINIDE; POTASSIUM CHANNEL BLOCKING AGENT; PROCAINAMIDE; PROPAFENONE; PROPRANOLOL; QUINIDINE; RSD 1235; SODIUM CHANNEL BLOCKING AGENT; SOTALOL; TEDISAMIL; TRECETILIDE; TROPONIN I; TROPONIN T; UNCLASSIFIED DRUG;

ANTICOAGULATION; BRADYCARDIA; CARDIOVERSION; CLINICAL TRIAL; CONSTIPATION; CORONARY SINUS; DEFIBRILLATION; DEFIBRILLATOR; DRUG MECHANISM; EMBOLISM; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART PROARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HUMAN; HYPOTENSION; INCIDENCE; META ANALYSIS; NAUSEA; PHLEBITIS; QRS COMPLEX; QT INTERVAL; REVIEW; SIDE EFFECT; SINUS RHYTHM; SYSTEMATIC REVIEW; TECHNIQUE; TORSADE DES POINTES; TREATMENT OUTCOME; VISUAL DISORDER;

EID: 27144451207     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcad.2005.06.006     Document Type: Article

References (133)

1. A.J. Joglar, and R.J. Schwarzberg EP lab Digest 3 2003 1 3
2. D.G. Wyse, A.L. Waldo, and J.P. DiMarco A comparison of rate control and rhythm control in patients with atrial fibrillation N Engl J Med 347 2002 18525 18533
3. L. Carl Enige neue Versuche uber Herzbewegung Zeitschrift Rationelle Medizin 9 1850 107 144
4. W.B. Fye Ventricular fibrillation and defibrillation: Historical perspectives with emphasis on the contributions of John McWilliam, Carl Wiggers and William K Circulation 71 1985 858 865
5. J.L. Prevost, and F. Batelli La Mort Par Les Descharges Electriques J. Physiol. 1899 1085 1100
6. S. Borys Brief history of cardiac arrhythmias since the end of the nineteenth century J. Cardiovasc. Electrophysiol. 15 2004 101 104
7. C.S. Beck Ventricular defibrillation of long duration abolished by electrical shock JAMA 135 1947 985 988
8. L. Berndt Historical perspectives on interventional electrophysiology J. Interv. Card. Electrophysiol. 9 2003 75 83
9. B. Lown Cardioversion of atrial fibrillation N. Engl. J. Med. 269 1963 325 331
10. B. Lown, R. Amarasingham, and J. Neuman New method for treating cardiac arrhythmias; Use of synchronized capacitor discharge JAMA 182 1962 548 555
11. S. Alexander The new era of cardioversion JAMA 256 1986 628 629
12. M.E. Silverman History and personal observations of electrical cardioversion of atrial fibrillation Am. J. Cardiol. 94 2004 751 752
13. C.J. Hou, P. Chang-Sing, and E. Flynn Determination of ventricular vulnerable period and ventricular fibrillation threshold by use of T-wave shocks in patients undergoing implantation of cardioverter/defibrillators Circulation 92 1995 2558 2564
14. M.M. Mower, M. Mirowski, and J.F. Spear Patterns of ventricular activity during catheter defibrillation Circulation 49 1974 858 861
15. D.P. Zipes, J. Fischer, and R.M. King Termination of ventricular fibrillation in dogs by depolarizing a critical amount of myocardium Am. J. Cardiol. 36 1975 37 44
16. F.X. Witkowski, P.A. Penkoske, and R. Plonsey Mechanism of cardiac defibrillation in open-chest dogs with unipolar DC-coupled simultaneous activation and shock potential recordings Circulation 82 1990 244 260
17. P.S. Chen, J. Fischer, and R.M. King Mechanism of cardiac defibrillation: A different point of view Circulation 84 1991 913
18. F.X. Witkowski, and R.E. Kerber Currently known mechanisms underlying direct current external and internal cardiac defibrillation J. Cardiovasc. Electrophysiol. 2 1991 562
19. P.S. Chen, P.D. Wolf, and R.E. Ideker Mechanism of cardiac defibrillation: A different point of view Circulation 84 1991 913 919
20. P.S. Chen, N. Shibata, and E.G. Dixon Comparison of the defibrillation threshold and the upper limit of ventricular vulnerability Circulation 73 1986 1022 1028
21. J. Huang, B.H. KenKnight, and G.P. Walcott Effects of transvenous electrode polarity and waveform duration on the relationship between defibrillation threshold and upper limit of vulnerability Circulation 96 1997 1351 1359
22. S. Mittal, S. Ayati, and K.M. Stein Transthoracic cardioversion of atrial fibrillation. Comparison of rectilinear biphasic versus damped sine wave monophasic shocks Circulation 101 2000 1282 1287
23. G.W. Dalzell, S.R. Cunningham, and Anderson Electrode pad size, transthoracic impedance and success of external ventricular defibrillation Am. J. Cardiol. 64 1989 741 744
24. P.N. Connell, G.A. Ewy, and C.F. Dahl Transthoracic impedance to defibrillator discharge: Effect of electrode size and electrode-chest wall interface J. Electrocardiol. 6 1973 313 316
25. B. Lown Cardioversion of atrial fibrillation: A report on the treatment of 65 episodes in 50 patients N. Engl. J. Med. 269 1963 325 331
26. G.L. Botto, A. Politi, and W. Bonini External cardioversion of atrial fibrillation: Role of paddle position on technical efficacy and energy requirements Heart 82 1999 726 730
27. C.F. Dahl, G.A. Ewy, and E.D. Warner Myocardial necrosis from direct current countershock: Effect of paddle electrode size and time interval between discharges Circulation 50 1974 956 961
28. A.J. Jose, M.D. Joglar, and C.K. Robert Electrical cardioversion of atrial fibrillation Cardiol. Clin. 22 2004 314 317
29. J. Jones, J. Swartz, and R.E. Jones Increasing fibrillation duration enhances relative asymmetrical biphasic versus monophasic defibrillator waveform efficacy Circ. Res. 67 1990 376 384
30. E. Fain, M.B. Sweeney, and M.R. Franz Improved internal defibrillation efficacy with a biphasic waveform Am. Heart. J. 117 1989 358 364
31. D.G. Wyse, D.G. Wyse, and K.M. Kavanagh Comparison of biphasic and monophasic shocks for defibrillation using a nonthoracotomy system Am Cardiol 71 1993 197 202
32. T.S. Takata, R.L. Page, and J.A. Joglar Automated external defibrillators: Technical considerations and clinical promise Ann Intern Med 135 2001 990 998
33. P. Ricard, S. Levy, and J. Trigano Prospective assessment of the minimum energy needed for external electrical cardioversion of atrial fibrillation Am. J. Cardiol. 79 1997 815 816
34. J.A. Joglar, M.H. Hamdan, and K.R. Ramaswamy Initial energy for elective external cardioversion of persistent atrial fibrillation Am. J. Cardiol. 86 2000 348 350
35. S.L. Pinski, E.B. Sgarbossa, and E. Ching A comparison of 50 J versus 100 J shocks for direct current cardioversion of atrial flutter Am. Heart. J. 137 1999 439 442
36. M.F. Lesser Safety and efficacy of in-office cardioversion for treatment of supraventricular arrhythmias Am. J. Cardiol. 66 1990 1267 1268
37. I.C. Van Gelder, H.J. Crijns, and W.H. Van Gilst Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter Am. J. Cardiol. 68 1991 41 46
38. T. Sodermark, B. Jonsson, and A. Olsson Effect of quinidine on maintaining sinus rhythm after conversion of atrial fibrillation or flutter: A multicentre study from Stockholm Br. Heart J. 37 1975 486 492
39. S. Stephanos, J. Jung, and A. Buob Incidence and management of early recurrent atrial fibrillation (ERAF) after transthoracic electrical cardioversion Europace 6 2004 15 20
40. A. Chugh, M. Ozaydin, and C. Scharf Mechanism of immediate recurrences of atrial fibrillation after restoration of sinus rhythm Pacing Clin. Electrophysiol. 1 2004 77 78
41. D. Schwartzman, S.K. Musley, and C. Swerdlow Early recurrence of atrial fibrillation after ambulatory shock conversion J. Am. Coll. Cardiol. 3 2002 93 99
42. M. Frick, V. Frykman, and M. Jensen-Urstad Factors predicting success rate and recurrence of atrial fibrillation after first electrical cardioversion in patients with persistent atrial fibrillation Clin. Cardiol. 3 2001 238 244
43. S. Levy, P. Lacombe, and R. Cointe High energy transcatheter cardioversion of chronic atrial fibrillation J. Am. Coll. Cardiol. 12 1988 514 518
44. S. Levy, P. Lauribe, and E. Dolla A randomized comparison of external and internal cardioversion of chronic atrial fibrillation Circulation 86 1992 1415 1420
45. F.D. Murgatroyd, A.K. Slade, and S.M. Sopher Efficacy and tolerability of transvenous low energy cardioversion of paroxysmal atrial fibrillation in humans J. Am. Coll. Cardiol. 25 1995 1347 1353
46. E. Alt, C. Schmitt, and R. Ammer Initial experience with intracardiac atrial defibrillation in patients with chronic atrial fibrillation Pacing Clin. Electrophysiol. 17 1994 1067 1078
47. J.L. Burns, S.F. Sears, and R. Sotile Do patients accept implantable atrial defibrillation therapy? Results from the Patient Atrial Shock Survey of Acceptance and Tolerance (PASSAT) Study J. Cardiovasc. Electrophysiol. 15 2004 286 291
48. M.R. Gold, N. Sulke, and D.S. Schwartzman Clinical experience with a dual-chamber implantable cardioverter defibrillator to treat atrial tachyarrhythmias J. Cardiovasc. Electrophysiol. 12 2001 1247 1253
49. R. Khaddaha, D.D. Narula, and F. Fefer Atrial defibrillation using the conventional implantable cardioverter defibrillator J. Am. Coll. Cardiol. 33 1999 146
50. A.I. Lukoshevichiute Use of esophageal electric countershock Kardiologiia 18 1978 12 20
51. G. Moe On the multiple wavelet hypothesis of atrial fibrillation Arch. Int. Pharmacodyn. Ther. 140 1962 183 188
52. M.A. Allessie, W.J. Lammers, and F.I. Bonke Experimental evaluation of Moe's multiple wavelet hypothesis of AF Cardiac arrhythmias 1985 Grune and Stratton 265 276
53. M.A. Allessie, F.I. Bonke, and F.J. Schopman Circus movement in rabbit atrial muscle as a mechanism of tachycardia. III. The "leading circle" concept: A new model of circus movement in cardiac tissue without the involvement of an anatomical obstacle Circ. Res. 41 1977 9 18
54. P.L. Rensma, M.A. Allessie, and W.J. Lammers Length of excitation wave and susceptibility to reentrant atrial arrhythmias in normal conscious dogs Circ. Res. 62 1988 395 410
55. L. Yue, J. Feng, and R. Gaspo Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation Circ. Res. 81 1997 512 525
56. R.F. Bosch, C.R. Scherer, and N. Rub Molecular mechanisms of early electrical remodeling: Transcriptional down regulation of ion channel subunits reduces I(Ca,L) and I(to) in rapid atrial pacing in rabbits J. Am. Coll. Cardiol. 41 2003 858 869
57. S. Nattel New ideas about atrial fibrillation 50 years on Nature 415 2002 219 226
58. J. Ehrlich, P. Kowey, and A. Nacarelli Pharmacological cardioversion of atrial fibrillation 2005 182 (chapter 9)
59. D.S. Echt, P.R. Liebson, and L.B. Mitchell Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The cardiac arrhythmia suppression trial N. Engl. J. Med. 324 1991 781 788
60. S.E. Coplen, E.M. Antman, and J.A. Berlin Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials Circulation 82 1990 1106 1116
61. J. Reisinger, E. Gatterer, and G. Heinze Prospective comparison of flecainide versus sotalol for immediate cardioversion of atrial fibrillation Am. J. Cardiol. 81 1998 1450 1454
62. M.J. Suttorp, J.H. Kingma, and L. Lie-A-Huen Intravenous flecainide versus verapamil for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm Am. J. Cardiol. 63 1989 693 696
63. J. Jalife, O. Berenfeld, and M. Mansour Mother rotors and fibrillatory conduction: A mechanism of atrial fibrillation Cardiovasc. Res. 54 2002 204 216
64. J. Kneller, J. Leon, and S. Nattel How do class I antiarrhythmic drugs terminate atrial fibrillation? A quantitative analysis based on a realistic ionic model Circulation 104 2001 ab5
65. A. Kawase, I. Takanori, and N. Kazuo Widening of the excitable gap and enlargement of the core of reentry during atrial fibrillation with a pure sodium channel blocker in canine atria Circulation 107 2003 905 910
66. M.A. Vos, S.R. Golitsyn, and K. Stangl Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation Heart 79 1998 568 575
67. K.A. Ellenbogen, B.S. Stambler, and M.A. Wood Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: A dose-response study J. Am. Coll. Cardiol. 28 1996 130 136
68. B.S. Stambler, M.A. Wood, and K.A. Ellenbogen Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation Circulation 94 1996 1613 1621
69. B.S. Stambler, M.A. Wood, and K.A. Ellenbogen Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation: Electrophysiologic determinants of enhanced conversion efficacy Circulation 96 1997 4298 4300
70. A.S. Volgman, P.A. Carberry, and B. Stambler Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation J. Am. Coll. Cardiol. 31 1998 1414 1418
71. H. Oral, J.J. Souza, and G.F. Michaud Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment N. Engl. J. Med. 340 1999 1849 1852
72. E. Galve, T. Rius, and R. Ballester Intravenous amiodarone in treatment of recent-onset atrial fibrillation: Results of a randomized, controlled study J. Am. Coll. Cardiol. 27 1996 1079 1082
73. P. Chevalier, A. Durand-Dubief, and H. Bum Amiodarone versus placebo and classic drugs for cardioversion of recent-onset atrial fibrillation: A meta-analysis J. Am. Coll. Cardiol. 41 2003 255 262
74. N.J. Alp, J.A. Bell, and M. Shahi Randomised double blind trial of oral versus intravenous flecainide for the cardioversion of acute atrial fibrillation Heart 84 2000 37 40
75. L. Lie-A-Huen, J.H. Proost, and J.H. Kingma Absorption kinetics of oral and rectal flecainide in healthy subjects Eur J Clin Pharmacol 38 1990 595 598
76. K. Hage, K. Buhl, and C. Fischer Estimation of the absolute bioavailability of flecainide using stable isotope technique Eur. J. Clin. Pharmacol. 48 1995 51 55
77. I.A. Khan, I.A. Khan, and N.J. Mehta Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation J. Am. Coll. Cardiol. 37 2001 542 547
78. P. Alboni, G.L. Botto, and N. Baldi Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach N. Engl. J. Med. 351 2004 2384 2391
79. R. Greenbaum, T.J. Campbell, and K.S. Charmer Conversion of atrial fibrillation and Maintenance of sinus rhythm by dofetilide. The EMERALD study Circulation 98 1998 1 633
80. C. Torp-Pedersen, M. Moller, and P.E. Bloch-Thomsen Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group N. Engl. J. Med. 341 1999 857 865
81. S. Singh Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: The Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) study Circulation 102 2000 2385 2390
82. R. Greenbaum Conversion of atrial fibrillation and Maintenance of sinus rhythm by dofetilide Circulation 98 1998 I-633 (Suppl I)
83. S. Singh, R.G. Zoble, and L. Yellen Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: The Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) study Circulation 102 2000 2385 2390
84. R.H. Falk, A. Pollak, and S.N. Singh Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous dofetilide investigators J. Am. Coll. Cardiol. 29 1997 385 390
85. B.L. Norgaard, K. Wachtell, and P.D. Christensen Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: A multicenter, randomized, double-blind, placebo-controlled trial Am. Heart. J. 137 1999 1062 1069
86. L. Frost, P.E. Mortensen, and J. Tingleff Efficacy and safety of dofetilide, a new class III antiarrhythmic agent, in acute termination of atrial fibrillation or flutter after coronary artery bypass surgery Int. J. Cardiol. 58 1997 135 140
87. C.M. Pratt, J.N. Ruskin, and T. Friedrieck Dofetilide use in atrial fibrillation: A treatment strategy to minimize proarrhythmic risk J. Am. Coll. Cardiol. 35 2000 154A (Suppl A)
88. C.M. Pratt, S.N. Singh, and H.R. Al-Khalidi The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction J. Am. Coll. Cardiol. 43 2004 1211 1216
89. E.L. Pritchett, R.L. Page, and S.J. Connolly Antiarrhythmic effects of azimilide in atrial fibrillation: Efficacy and dose-response. Azimilide Supraventricular Arrhythmia Program 3 (SVA-3) Investigators J. Am. Coll. Cardiol. 36 2000 794 802
90. I.D. Dukes, L. Cleemann, and M. Morad Tedisamil blocks the transient and delayed rectifier K+ currents in mammalian cardiac and glial cells J. Pharmacol. Exp. Ther. 254 1990 560 569
91. D. Pfrunder, and V.A. Kreye Tedisamil inhibits the delayed rectifier K+ current in single smooth muscle cells of the guinea-pig portal vein Pflugers Arch. 421 1992 22 25
92. J.G. McLarnon Tedisamil blocks a calcium-dependent potassium channel in cultured motoneurons Neurosci. Lett. 144 1992 185 188
93. D. Pfrunder, and V.A. Kreye Tedisamil blocks single large-conductance Ca(2+)-activated K+ channels in membrane patches from smooth muscle cells of the guinea-pig portal vein Pflugers Arch. 418 1991 308 402
94. J. Faivre, S. Rouanet, and A. Bril Tedisamil inhibition of ATP-sensitive K+ channels in adult rat ventricular cells J. Mol. Cell. Cardiol. 24 1992 S40
95. L. Chi, J.L. Park, and G.S. Friedrichs Effects of tedisamil (KC-8857) on cardiac electrophysiology and ventricular fibrillation in the rabbit isolated heart Br J. Pharmacol. 117 1996 1261 1269
96. I.D. Dukes, and M. Morad Tedisamil inactivates transient outward K+ current in rat ventricular myocytes Am. J. Physiol. 257 1989 1746 1749
97. J. Faivre, S. Rouanet, and A. Bril Comparative effects of glibenclamide, tedisamil, dofetilide, E-4031 and BRL-32872 on protein kinase A-activated chloride current in guinea pig ventricular myocytes J. Cardiovasc. Pharmacol. 31 1988 551 557
98. K. Bargheer, F. Bode, and H.U. Klein Prolongation of monophasic action potential duration and the refractory period in the human heart by tedisamil, a new potassium-blocking agent Eur. Heart J. 15 1994 1409 1414
99. E. Wettwer, H.M. Himmel, and G.J. Amos Mechanism of block by tedisamil of transient outward current in human ventricular subepicardial myocytes Br. J. Pharmacol. 125 1998 659 666
100. J. Hester, J.K. Gibson, and L.V. Buchanan Progress toward the development of a safe and effective agent for treating reentrant cardiac arrhythmias: Synthesis and evaluation of ibutilide analogues with enhanced metabolic stability and diminished proarrhythmic potential J. Med. Chem. 44 2001 1099 1115
101. S. Buist, C.Y. Hsu, and R.R. Walters Sensitive determination of a new antiarrhythmic agent, trecetilide, in plasma by high-performance liquid chromatography with fluorescence detection J. Chromatogr. 828 1998 259 265
102. Castro, L. Bianconi, and M. Santini New antiarrhythmic drugs for the treatment of atrial fibrillation Pacing Clin. Electrophysiol. 25 2002 249 259
103. A.S. Manning, C. Bruyninckx, and J. Ramboux A new amiodarone-like agent: Effect on ischemia and reperfusion induced arrhythmias in anesthetized rats J. Cardiovasc. Pharmacol. 26 1995 453 461
104. P. Chatelain, L. Meysmans, and J.R. Matteazzi Interaction of the antiarrhythmic agents SR 33589 and amiodarone with the beta-adrenoceptor and adenylate cyclase in rat heart Brit. J. Pharmacol. 116 1995 1949 1956
105. D. Hodeige, J.P. Heyndrickx, and P. Chatelain A new amiodarone like antiarrhythmic agent: Anti-adrenoceptor activity in anesthetized and conscious dogs Eur. J. Pharmacol. 279 1995 25 32
106. A. Manning, V. Thisse, and D. Hodeige A new amiodarone like antiarrhythmic agent: Electrophysiological effects in anesthetized dogs J. Cardiovasc. Pharmacol. 25 1995 252 261
107. G.N. Beatch, S.P. Lin, and J.C. Hesketh Electrophysiological mechanism of RSD1235, a new atrial fibrillation converting drug Circulation 108 2002 IV85 (Suppl IV)
108. G.N. Beatch, K. Shinagawa, and B. Johnson RSD1235 selectively prolongs atrial refractoriness and terminates AF in dogs with electrically remodeled atria Pacing Clin. Electrophysiol. 25 2002 698 699
109. Roy, B.H. Rowe, and I.G. Stiell A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation J. Am. Coll. Cardiol. 44 2004 2355 2361
110. A.J. José, and L.P. Richard Early recurrence of atrial fibrillation J. Cardiovasc. Electrophysiol. 15 2004 898 900
111. W. Saliba, N. Juratli, and M.K. Chung Higher energy synchronized external direct current cardioversion for refractory atrial fibrillation J. Am. Coll. Cardiol. 34 1999 2031 2034
112. G. Gasparini, A. Bonso, and S. Themistoclakis Low-energy internal cardioversion in patients with long-lasting atrial fibrillation refractory to external electrical cardioversion: Results and long-term follow-up Europace 3 2001 90 95
113. M. Kabukca, F. Demircioglu, and E. Yanik Simultaneous double external DC shock technique for refractory atrial fibrillation in concomitant heart disease Jpn. Heart J. 45 2004 929 936
114. I.C. Van Gelder, H.J. Crijns, and R.G. Tieleman Chronic atrial fibrillation: Success of serial cardioversion therapy and safety of oral anticoagulation Arch. Intern. Med. 156 1996 2585 2592
115. V Fuster, L.E. Ryden, and R.W. Asinger ACC/AHA/ESC Guidelines for the management of patients with atrial fibrillation J. Am. Coll. Cardiol. 38 2001 1266 1299
116. E.J. Barnes, F. Eben, and D. Patterson Direct current cardioversion during pregnancy should be performed with facilities available for fetal monitoring and emergency caesarean section BJOG 109 2002 1406 1407
117. W. Deborah Treatment of arrhythmias during pregnancy Curr. Womens Health Rep. 3 2003 135 139
118. A. Sacchetti, V. Moyer, and R. Baricella Primary cardiac arrhythmias in children Pediatr. Emerg. Care 15 1999 95 98
119. A.D.J. Radford, and T. Izukawa Atrial fibrillation in children Pediatrics 59 1977 250 256
120. C.J. Bjerkelund, and O.M. Orning The efficacy of anticoagulant therapy in preventing embolism related to DC electrical conversion of atrial fibrillation Am. J. Cardiol. 23 1969 208 216
121. A.Z. Arnold, M.J. Mick, and R.P. Mazurek Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter J. Am. Coll. Cardiol. 19 1992 851 855
122. M.D. Rabbino Complications and limitations of direct current countershock JAMA 190 1964 417 420
123. B. Lown, W. Likoff, and L.S. Dreifus Cardioversion and digitalis drugs: Changed threshold to electric shock in digitalized animals Circ. Res. 17 1965 519 531
124. H. Aberg, and I. Cullhed Direct current countershock complications Acta Med. Scand. 183 1968 415 421
125. R.V. Ditchey, and J.S. Karliner Safety of electrical cardioversion in patients without digitalis toxicity Ann. Intern. Med. 95 1981 676 679
126. G.B. Mancini, and A.L. Goldberger Cardioversion of atrial fibrillation: Consideration of embolization, anticoagulation, prophylactic pacemaker, and long-term success Am. Heart. J. 104 1982 617 621
127. D.P. Lipkin, M. Frenneaux, and R. Stewart Delayed improvement in exercise capacity after cardioversion of atrial fibrillation to sinus rhythm Br. Heart J. 59 1988 572 577
128. J.N. Patton, J.D. Allen, and J.F. Pantridge The effects of shock energy, propranolol, and verapamil on cardiac damage caused by transthoracic countercheck Circulation 69 1984 357 368
129. I.C. Van Gelder, H.J. Crijns, and L.A. Van der Incidence and clinical significance of ST segment elevation after electrical cardioversion of atrial fibrillation and atrial flutter Am. Heart. J. 121 1991 51 56
130. A. Ehsani, G.A. Ewy, and B.E. Sobel Effects of electrical countershock on serum creatine phosphokinase (CPK) isoenzyme activity Am. J. Cardiol. 37 1976 12 18
131. Pagan-Carlo, M.S. Stone, and R.E. Kerber Nature and determinants of skin burns after transthoracic cardioversion Am. J. Cardiol. 79 1997 689 691
132. R.L. Page, R.E. Kerber, and J.K. Russell Biphasic versus monophasic shock waveform for conversion of atrial fibrillation: The results of an international randomized, double-blind multicenter trial J. Am. Coll. Cardiol. 39 2002 1956 1963
133. Verdino, J.J. Teuteberg, and M.C. Burke Successful cardioversion of atrial fibrillation in-patients referred to an electrophysiologist for internal cardioversion Clin. Cardiol. 24 2001 500 502